Next-Generation Nanobody Targeting ALB and IL13 for Innovative Autoimmune Disease Therapy
VHH-P400 is a biologically engineered, humanized single-domain antibody (nanobody) designed to precisely target both albumin (ALB) and interleukin 13 (IL13). Currently in the Biological Testing stage, VHH-P400 leverages the full-length names—albumin (ALB) and interleukin 13 (IL13)—ensuring enhanced therapeutic potential for addressing the challenges of autoimmune disease. By binding to these two critical molecules, VHH-P400 represents a novel approach aiming to improve treatment outcomes in autoimmune pathologies. The program is positioned to offer a new level of selectivity, stability, and delivery for unmet medical needs in this rapidly evolving field.
| Candidate | VHH-P400 |
| Target | albumin (ALB) interleukin 13 (IL13) |
| Modality | humanized bispecific VHH |
| Indication | Autoimmune Disease |
Licensing Opportunity
VHH-P400 is available for licensing opportunities. We invite pharmaceutical and biotechnology partners to collaborate in advancing this innovative nanobody program targeting ALB and IL13 for autoimmune disease therapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P400 |
Modality
VHH-P400 employs a modular and compact design that consists of humanized single-domain antibodies (VHH) fused through flexible (G4S)4 linkers, all expressed in the robust Pichia pastoris system. Thanks to its nanobody backbone, VHH-P400 features a small molecular size, high stability, and deep tissue penetration, allowing for efficient access to inflamed or fibrotic tissue compartments often seen in autoimmune disease. The fusion to ALB-targeting and dual IL13-targeting VHH elements enhances both in vivo half-life and functional potency. This structure offers superior formulation flexibility and manufacturing scalability, crucial for developing advanced biologics targeting complex autoimmune indications.
Target
VHH-P400 is designed to simultaneously target ALB and IL13, two key molecules implicated in autoimmune disease biology. ALB is the most abundant serum protein, essential for maintaining osmotic pressure and serving as a carrier for multiple biomolecules. Predominantly synthesized in the liver, ALB also modulates drug pharmacokinetics and biodistribution. IL13 is a cytokine central to immune regulation, mainly produced by T-helper type 2 cells, and is critically involved in inflammation, tissue remodeling, and immune dysregulation processes. Aberrant ALB and IL13 signaling contribute to the pathogenesis of many autoimmune disorders. By engaging ALB and IL13, VHH-P400 addresses immunopathological cascades at two strategic points, with the dual-target approach enhancing its value for future autoimmune disease therapies.
Mechanism of Action
VHH-P400 exerts its effect by simultaneously engaging ALB and IL13, modulating key signaling pathways in autoimmune disease. The anti-ALB component extends the molecule’s systemic circulation and can alter pharmacokinetics, potentially facilitating sustained therapeutic exposure. Anti-IL13 VHH modules bind specifically to IL13, interrupting its interaction with cellular receptors, thereby suppressing downstream signaling events associated with inflammation and immune dysregulation. Through this multi-pronged mechanism—spanning half-life extension to direct cytokine neutralization—VHH-P400 offers new opportunities for therapeutic intervention. The nanobody platform underlying VHH-P400 also enables future adaptations (such as bispecifics or conjugates), supporting broad application in next-generation biologics development.
Autoimmune Disease
Autoimmune diseases encompass a large and diverse group of conditions arising from inappropriate immune responses against self-antigens. Collectively, these disorders affect millions worldwide and represent a significant health and socioeconomic burden. Common autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, among others. Current management typically relies on immunosuppressants, corticosteroids, and targeted biologics; however, many of these approaches are associated with systemic adverse effects, incomplete efficacy, or increased infection risk. Unmet needs remain for therapies providing greater selectivity, durability, and improved safety. VHH-P400’s unique dual targeting of ALB and IL13 offers a new method to modulate disease-driving pathways and optimize pharmacokinetics, holding considerable promise to address therapeutic gaps and improve patient outcomes in autoimmune disease.